Increased Cellular Death [PE] - N0000009176

Name: Table of NDC products with increased cellular death
Creator: U.S. Food & Drug Administration
License: https://creativecommons.org/licenses/by-nc-sa/4.0/

Pharmacologic Class Information

Pharmacologic Code	N0000009176
Pharmacologic Name	Increased Cellular Death
Pharmacologic Uses	BCL-2 inhibitor CD22-directed antibody-drug conjugate (ADC) inducer of cell death
Pharmacologic Concept	Physiologic Effects - [PE]
Pharmacologic Concept Description	This concept refers to the tissue, organ, or organ system effects of drug generic ingredients, organized into an organ system classification hierarchy, beneath the "Physiological Effects [PE]" concept.

NDC Products with Increased Cellular Death

The table contains 4 products whose active ingredient are classified under the same pharmacologic class Increased Cellular Death [PE].

NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
0008-0100	Besponsa	Non-Proprietary Name: Inotuzumab Ozogamicin	Injection, Powder, Lyophilized, For Solution	Intravenous	Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.	ACTIVE
0074-0561	Venclexta	Non-Proprietary Name: Venetoclax	Tablet, Film Coated	Oral	Abbvie Inc.	ACTIVE
0074-0566	Venclexta	Non-Proprietary Name: Venetoclax	Tablet, Film Coated	Oral	Abbvie Inc.	ACTIVE
0074-0576	Venclexta	Non-Proprietary Name: Venetoclax	Tablet, Film Coated	Oral	Abbvie Inc.	ACTIVE